Good News for the Bubble Baby Disease Treatment Backed by Millions from California Taxpayers
By David Jensen,
The California Stem Cell Report
| 02. 15. 2022
Photo: CIRM
Twenty children seeking treatment for a rare affliction called the “bubble baby disease” today have some big-time, good news concerning a life-saving genetic therapy that they were once denied as the result of a tangled affair involving private profit and the public funding of cutting-edge scientific research.
After being halted nearly two years ago, a California state-financed clinical trial that can help the children is now solidly on its way to a new beginning at UCLA. Treatments of the children could begin as early as June.
The California stem cell agency is expected to provide $5.8 million to resume the trial at UCLA. Millions more are likely to be forthcoming from the agency, officially known as the California Institute for Regenerative Medicine (CIRM).
Despite the success of the trial over the last several years -- “100 percent overall survival” of 50 patients -- it was abandoned in 2020 by Orchard Therapeutics, PLC. Instead, Orchard turned towards research that it deemed would be more profitable. At that time, Orchard had exclusive rights to the therapy, which was...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...
